Powder: -20°C for 3 years | In solvent: -80°C for 2 years
KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 6-8 weeks | $ 970.00
$ 776.00
|
|
50 mg | 6-8 weeks | $ 1,980.00
$ 1,584.00
|
|
100 mg | 6-8 weeks | $ 2,500.00
$ 2,000.00
|
Description | KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines. |
In vitro | KU14R partially attenuated responses to Imidazole-4-acetic acid-ribotide (IAA-RP). Insulin Receptor A new I(3)-R antagonist, KU14R (2 (2-ethyl 2,3-dihydro-2-benzofuranyl)-2-imidazole), which selectively blocks the insulin secretory response to imidazolines. By measuring KATP channel activity, plasma membrane potential, cytosolic calcium concentration ([Ca2+]c), and dynamic insulin secretion to compare the effects of KU14R on stimulus secretion-coupling in normal mouse islets and beta cells. KU14R (30, 100 or 300 micromol/l) was ineffective, in the presence of 10 mmol/l but not of 5 mmol/l glucose. KATP channel was blocked by KU14R (IC50 31.9 micromol/l, Hill slope -1.5). KU14R does not act as an antagonist of either efaroxan or S22068 at an imidazoline site in vivo. |
Molecular Weight | 214.26 |
Formula | C13H14N2O |
CAS No. | 189224-48-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KU14R 189224-48-4 Others KU-14R inhibitor inhibit